title: Use of recombinant alpha-2b-interferon in combination with antioxidants in the form of rectal suppositories (viferon) in children with chronic hepatitides B and C.
abstract: A new antiviral and immunomodulating preparation Viferon, produced as rectal suppositories containing recombinant alpha-2b-interferon (IFN) and antioxidants, was used in complex therapy of viral chronic hepatitides B and C (ChHB and ChHC) in children. Results of our investigation showed a high efficiency of Viferon. Viferon was found to suppress replication of hepatotropic viruses and to decrease activity of the pathologic process in the liver of children with ChHB and ChHC. After a Viferon treatment with daily doses of (1-2) x 10(6) IU of IFN (3.0 x 10(6) IU/m2) primary remission was registered in 78% of patients with ChHB and in 44% of patients with ChHC, while lasting remission was found in 82% of ChHB and in 33% of ChHC patients. Thus, a more marked effect was observed with ChHB, in which 3.0 x 10(6) IU/m2 was the optimal daily dose for children. Increasing the dose to 5.0 x 10(6) IU/m2 did not result in rise of the percentage of the remissions. Side effects, which are characteristic for injection of IFN preparations, were never found even after a longterm treatment. Absence of induction of neutralizing antibodies was observed after administration of alpha-2b-IFN, an integral part of Viferon. In pediatrics, the method of rectal administration has advantages over parenteral delivery due to its convenience, non-traumatic character and possibility of use for prolonged periods.
authors.affiliation: Russian State Medical University, Moscow, Russia.
authors.forename: V
authors.initials: V
authors.lastname: Uchaikin
authors.forename: T
authors.initials: T
authors.lastname: Cherednichenko
authors.forename: V
authors.initials: V
authors.lastname: Malinovskaya
authors.forename: T
authors.initials: T
authors.lastname: Orlova
authors.forename: O
authors.initials: O
authors.lastname: Kovalev
authors.forename: F
authors.initials: F
authors.lastname: Kharlamova
authors.forename: G
authors.initials: G
authors.lastname: Chaplygina
authors.forename: V
authors.initials: V
authors.lastname: Konev
authors.forename: F
authors.initials: F
authors.lastname: Voronina
authors.forename: N
authors.initials: N
authors.lastname: Delenian
mesh_terms: D000293:Adolescent; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000276:immunology; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007223:Infant; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D011994:Recombinant Proteins; D013488:Suppositories; D013601:T-Lymphocytes / Q000276:immunology; D016896:Treatment Outcome; D014810:Vitamin E / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000975:Antioxidants; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D013488:Suppositories; D014810:Vitamin E; D001205:Ascorbic Acid